Focus:
Analysis
-
![Stop ignoring the two billion: pharma’s role in expanding access to medicine]()
Stop ignoring the two billion: pharma’s role in expanding access to medicine
Despite pharma’s growing commitment to broadening access to medicines in poorer countries, progress has been fragile, according to a ten-year review by the Access to Medicine Foundation. Pharma Tech Focus...
-
![NICE cancer guidance: good news for Ibrance and Lynparza]()
NICE cancer guidance: good news for Ibrance and Lynparza
The UK’s pricing regulator NICE decides whether new therapies are sufficiently cost-effective for NHS use. In its most recent publishing of guidance, NICE determined two oncology drugs – Pfizer’s Ibrance...
-
![What does ‘ageing’ mean when it comes to drug development?]()
What does ‘ageing’ mean when it comes to drug development?
The WHO is considering a new framework, which proposes the classification of aging as a condition in all organs, along with the comprehensive classification of all ageing-related diseases. This will...
-
![Twitter round-up: Neurology tweets – David Perlmutter’s tweet on meditation most popular in December 2019]()
Twitter round-up: Neurology tweets – David Perlmutter’s tweet on meditation most popular in December 2019
Pharmaceutical Technology lists ten of the most popular tweets on neurology in December 2019, based on data from GlobalData’s Influencer Platform. The top tweets were chosen from influencers as tracked...
-
![No more siloes: linking rheumatology and CVD with Abcentra]()
No more siloes: linking rheumatology and CVD with Abcentra
Although there are evidence-based links between CVD and inflammatory conditions, and associated strong risk factors, they are often ignored when treating patients with either type of condition. Abcentra former CEO...
-
![The rise of fake medicines in Africa]()
The rise of fake medicines in Africa
According to the World Health Organization, sham drugs are the world’s most lucrative counterfeit goods, with a global market worth roughly $200bn, and Africa accounts for around 42% of the...
-
![2019 top news stories]()
2019 top news stories
BMS acquires Celgene for an equity value of $74bn and GSK signs $4.2bn immunotherapy deal with the Merck group. Pharmaceutical-technology.com wraps up key headlines from 2019.
-
![Twitter round-up: Peter Hotez’s tweet on the false link between vaccines and autism trends in November 2019]()
Twitter round-up: Peter Hotez’s tweet on the false link between vaccines and autism trends in November 2019
Pharmaceutical Technology lists ten of the top tweets on infectious diseases in November 2019, based on data from GlobalData’s Influencer Platform. The top tweets were chosen from influencers as tracked...
-
![Debate: can US pharma be taxed into behaving?]()
Debate: can US pharma be taxed into behaving?
In the US, Democratic primary candidate Pete Buttigieg has proposed a punitive tax on drugmakers that refuse to renegotiate drug prices. Could taxation be an effective and fair way of...
-
![PrEP drugs: is the NHS letting down patients at risk of HIV?]()
PrEP drugs: is the NHS letting down patients at risk of HIV?
The efficacy of HIV-prevention drug PrEP is long-established, but access to the drug in England is restricted to participants on the NHS Impact Trial. At least 15 men who were...
